GIPR and type 2 diabetes mellitus: Notably, genetically reduced HbA1c via GIPR/GLP1R was associated with reduced T2D risk, with both loci demonstrating consistent, directionally aligned effects consistent with their intended therapeutic targeting of metabolic pathways (Table S12).